Abstract: Provided is a blood collection container capable of suppressing contamination of plasma by white blood cells and components in white blood cells. A blood collection container according to the present invention includes a blood collection container main body, a plasma separation material stored in the blood collection container main body, and an aqueous solution stored in the blood collection container main body, in which a solute contained in the aqueous solution contains an anticoagulant, and a total concentration of the solute in the aqueous solution is 100 mM or more and 450 mM or less, or 1200 mM or more.

Abstract: The present invention provides an immunoassay method for assaying SARS-CoV-2, including a step of contacting a biological sample with a monoclonal antibody or an antibody fragment thereof that binds to a nucleocapsid protein of SARS-COV-2, wherein the monoclonal antibody or the antibody fragment thereof binds to the SARS-CoV-2 treated with a serine protease.

Abstract: Provided is a blood separation composition with which a partition wall can be satisfactorily formed even when the blood separation composition is stored for a long time. A blood separation composition according to the present invention contains an organic component having fluidity at 25° C. and fine powder silica, the fine powder silica including hydrophobic silica having a hydrophobicity of 60% or more as measured by a methanol wettability method.

Abstract: Provided is a method for measuring an anti-drug antibody that can be performed more simply and inexpensively than conventional methods. Provided is a double antigen bridging immunoassay using a capture nucleic acid and a tracer nucleic acid. By using the capture nucleic acid and the tracer nucleic acid in the double antigen bridging immunoassay, an anti-drug antibody can be measured simply and inexpensively. Furthermore, by using the tracer nucleic acid, it becomes possible to adopt a high sensitivity detection method utilizing a nucleic acid.

Abstract: An object of the present invention is to increase the reactivity of poly A polymerase with an oligonucleotide or a DNA in which the nucleic acid base at the 3?-end is chemically modified, and then to improve the sensitivity of detection through a PALSAR method or the like. The present invention relates to increasing the reactivity of poly A polymerase with an oligonucleotide or a DNA used for the nucleic acid medicine, in which the nucleic acid base at the 3?-end is chemically modified, and then adjusting the Mn2+ concentration during a poly A polymerase reaction, in a method of detecting the oligonucleotide, for a detection target that is an oligonucleotide or a DNA in which the nucleic acid base at the 3?-end is chemically modified, through steps of addition of poly A to the 3?-end of the oligonucleotide with poly A polymerase, capturing with a capture probe, and amplification by a PALSAR method or the like. Thus, the problem of the present invention is solved.

Abstract: The present invention provides a method of detecting and a method of quantifying oligonucleotides with more excellent specificity and quantitativity as compared to conventional signal amplification (PALSAR) measurement methods. In the present invention, the problem is solved by hybridizing a target oligonucleotide to be measured with a complementary nucleic acid probe (3?-complementary sequence of target sequence-5?), or hybridizing the target oligonucleotide to be measured having given bases such as poly(A) added thereto with a complementary nucleic acid probe (3?-complementary sequence of target oligonucleotide+complementary sequence of given bases-5?), decomposing and removing an incomplete hybridization product by using a single-strand-specific nuclease such as Si nuclease, and measuring the nucleic acid probe contained in a remaining complete hybridization product by a PALSAR method.

Abstract: The problem addressed by the present invention is to provide an immunological assay method using a monoclonal antibody and a kit including the monoclonal antibody, which can be used for assaying ICTP without requiring special facilities. This problem can be solved by a method for immunological assay of type I collagen C-terminal telopeptide in a biological sample, including contacting type I collagen C-terminal telopeptide with a monoclonal antibody that recognizes an amino acid sequence represented by GFDFSFLP (SEQ ID NO: 1) as an epitope.

Abstract: A method for estimating a cause of coagulation time prolongation includes 1) detecting a coagulation reaction end point Pe in a coagulation reaction curve of a subject blood specimen having a prolonged coagulation time; 2) calculating T(X), wherein T(X) represents a measurement point or time at which the coagulation reaction curve reaches X % of Pe, and X is a variable of greater than 0 and equal to or less than 100; and 3) estimating a cause of coagulation time prolongation of the subject blood specimen based on a form of T(X).

Abstract: Provided is a blood coagulation reaction analysis method. The method includes measuring a blood coagulation reaction of a subject specimen and acquiring first data for calculating a blood coagulation time of the subject specimen and second data for estimating a blood coagulation abnormality factor of the subject specimen, wherein the acquiring of the second data includes: obtaining a first derivative V(i) of a coagulation reaction curve R(i); and determining a point pk where V(i) assumes Xk before reaching a maximum value of V(i), Vmax, and a point qk where V(i) assumes Xk after reaching Vmax.

Abstract: Provided is a nucleic acid purification method capable of efficiently purifying a nucleic acid. The nucleic acid purification method including the steps of: mixing a nucleic acid with an antifoaming agent and a coprecipitation agent; and purifying the nucleic acid, in which the antifoaming agent is at least one of a nonionic surfactant and a silicone antifoaming agent.

Abstract: The present invention relates to latex particles for measurement reagents, said latex particles having a coefficient of variation in particle diameters of 10% or less and an average particle diameter of 250 to 1000 nm. Each of the latex particles contains 20% by weight or more of a compound having a refractive index of 1.60 or more. The depth of a supernatant is 5 mm or less when a liquid dispersion having a solid matter concentration of 1% by weight, which is prepared by dispersing the latex particles in ultrapure water, is placed in a tubular 10-ml measuring cylinder having a body inner diameter of 10.8 mm and is then allowed to leave for 10 days. According to the particles, a measurement of a measurement sample can be performed at a high sensitivity even when the concentration of a substance to be tested in the measurement sample is low.

Abstract: A method for detecting a blood coagulation reaction, comprising: 1) measuring a blood coagulation reaction of a subject blood specimen and acquiring a first derivative V(i) of a coagulation reaction up to a latest measurement point; 2) calculating areas under the curve (AUCs) before the peak and after the peak, wherein a top of the peak of V(i) is cVmax(k) which is a maximum value of V(i); and 3) detecting cVmax(k) as Vmax which is a true maximum value of V(i) when the pre-peak AUC and the post-peak AUC are both equal to or higher than a first threshold AUCth1 and a period L during which the pre-peak AUC and the post-peak AUC have continued to be a constant value reaches a predetermined length.

Abstract: An object of the present invention is to provide a method for measuring an object to be measured in a specimen by an enzymatic method, the measurement method being able to suppress the positive influence of peroxide derived from the specimen. More specifically, an object of the present invention is to provide a measurement method and a measurement reagent that can suppress elevation in value regardless of whether or not the specimen is a catalase-free specimen.

Abstract: Provided is a blood coagulation time measurement method. In the method, reaction X(i) is acquired through smoothing and zero-point adjustment of a measured value P(i) for coagulation reaction of a blood specimen, and then an integration ratio Z(i) of the reaction X(i) is acquired. These values are used to calculate an index for coagulation time Tc calculation, and it is determined whether or not the index satisfies the criteria. The procedure is sequentially repeated until an index that satisfies the criteria is obtained.

Abstract: Provided is a blood analysis method including: acquiring coagulation reaction data on a blood specimen; calculating a parameter related to a centroid point from a differential curve of the coagulation reaction data; and evaluating coagulation properties of the blood specimen using the parameter related to the centroid point.

Abstract: An object of the present invention is to provide a more sensitive detection method and quantification method in a method for detecting a target nucleic acid using the PALSAR method.

Abstract: Provided is an inspection chip with simplified channel switching structure, which is generally complicated.

Abstract: An object of the present invention is to provide a TARC-containing composition with high storage stability. Provided is a composition including TARC (Thymus and activation-regulated chemokine) and one or more selected from the group consisting of a sugar fatty acid ester-type nonionic surfactant, a polyoxyethylene-polyoxypropylene block copolymer-type nonionic surfactant, and a polyoxyethylene alkylamine-type nonionic surfactant and being in liquid form. The aforementioned object is achieved by the composition.

Abstract: An object of the present invention is to provide a TARC-containing composition with high storage stability. Provided is a composition including TARC (Thymus and activation-regulated chemokine) and a polymer having 2-methacryloyloxyethyl phosphorylcholine as a structural unit, and being in liquid form. The aforementioned object is achieved by the composition.

Abstract: There is provided a composition for separating blood serum or blood plasma that can inhibit bubbling during sterilization, and can inhibit the occurrence of phase separation during storage. The composition for separating blood serum or blood plasma according to the present invention comprises a (meth)acrylic acid ester-based polymer, a silica fine powder, and a silicone oil, wherein the (meth)acrylic acid ester-based polymer has fluidity at room temperature, and has a weight average molecular weight of 15000 or more and 100000 or less.